BioCentury | Jan 17, 2000
Company News

CpG Immuno autoimmune/inflammation, cancer, infectious diseases news

...CpG changed its name to Coley Pharmaceutical Group. CpG ImmunoPharmaceuticals Inc., Wellesley, Mass. Business: Autoimmune/Inflammation, Cancer, Infectious diseases WIR...
BioCentury | Nov 1, 1999
Company News

CpG Immuno management update

CpG ImmunoPharmaceuticals Inc., Wellesley, Mass. Business: Autoimmune/Inflammation, Cancer, Infectious diseases Hired: Aileen Ryan as VP of regulatory affairs, formerly VP of regulatory affairs and compliance at Asta Medica Inc. WIR Staff autoimmune cancer Infectious Inflammation...
BioCentury | Aug 9, 1999
Company News

CpG Immuno other research news

...dendritic cells, which present foreign antigens to the immune system and thus activate T cells. CpG ImmunoPharmaceuticals Inc....
BioCentury | Jun 14, 1999
Company News

CpG Immuno management update

CpG ImmunoPharmaceuticals Inc., Wellesley, Mass. Business: Infectious diseases Hired: Ralph Venhaus as VP of medical affairs, formerly VP of medical affairs at Asta Medica Inc. WIR Staff Infectious...
BioCentury | Apr 19, 1999
Clinical News

CpG 7909: Began Phase I study

CpG ImmunoPharmaceuticals Inc., Wellesley, Mass. Product: CpG 7909 Business: Infectious diseases Therapeutic category: Adjuvant, Immune stimulation Target: Immune cells Description: CpG-containing oligonucleotide Indication: Prevent hepatitis B infection Status: The company began a Phase I safety...
BioCentury | Jan 4, 1999
Clinical News

CpG Immuno preclinical data

...after birth, as did an HBV DNA vaccine, compared to 0-10 percent of control mice. CpG Immunopharmaceuticals Inc....
BioCentury | Nov 2, 1998
Tools & Techniques

Port of entry

...mucosa is cholera toxin, which works in rodents but is much too toxic for people. CpG ImmunoPharmaceuticals Inc....
BioCentury | Nov 2, 1998
Company News

CpG Immuno other research news

...Human testing is expected to start late this year with a vaccine for hepatitis B. CpG ImmunoPharmaceuticals Inc....
BioCentury | Oct 19, 1998
Company News

CpG Immuno other research news

...which they suggested could be important for development of DNA vaccines or gene therapy vectors. CpG ImmunoPharmaceuticals Inc....
BioCentury | Aug 24, 1998
Company News

CpG Immuno management update

CpG ImmunoPharmaceuticals Inc., Wellesley, Mass. Business: Infectious diseases, Cancer, Autoimmune/Inflammation Hired: Robert Bratzler, as president and CEO, formerly chairman and co-founder of Encore Pharmaceuticals Inc. WIR Staff...
Items per page:
1 - 10 of 13
BioCentury | Jan 17, 2000
Company News

CpG Immuno autoimmune/inflammation, cancer, infectious diseases news

...CpG changed its name to Coley Pharmaceutical Group. CpG ImmunoPharmaceuticals Inc., Wellesley, Mass. Business: Autoimmune/Inflammation, Cancer, Infectious diseases WIR...
BioCentury | Nov 1, 1999
Company News

CpG Immuno management update

CpG ImmunoPharmaceuticals Inc., Wellesley, Mass. Business: Autoimmune/Inflammation, Cancer, Infectious diseases Hired: Aileen Ryan as VP of regulatory affairs, formerly VP of regulatory affairs and compliance at Asta Medica Inc. WIR Staff autoimmune cancer Infectious Inflammation...
BioCentury | Aug 9, 1999
Company News

CpG Immuno other research news

...dendritic cells, which present foreign antigens to the immune system and thus activate T cells. CpG ImmunoPharmaceuticals Inc....
BioCentury | Jun 14, 1999
Company News

CpG Immuno management update

CpG ImmunoPharmaceuticals Inc., Wellesley, Mass. Business: Infectious diseases Hired: Ralph Venhaus as VP of medical affairs, formerly VP of medical affairs at Asta Medica Inc. WIR Staff Infectious...
BioCentury | Apr 19, 1999
Clinical News

CpG 7909: Began Phase I study

CpG ImmunoPharmaceuticals Inc., Wellesley, Mass. Product: CpG 7909 Business: Infectious diseases Therapeutic category: Adjuvant, Immune stimulation Target: Immune cells Description: CpG-containing oligonucleotide Indication: Prevent hepatitis B infection Status: The company began a Phase I safety...
BioCentury | Jan 4, 1999
Clinical News

CpG Immuno preclinical data

...after birth, as did an HBV DNA vaccine, compared to 0-10 percent of control mice. CpG Immunopharmaceuticals Inc....
BioCentury | Nov 2, 1998
Tools & Techniques

Port of entry

...mucosa is cholera toxin, which works in rodents but is much too toxic for people. CpG ImmunoPharmaceuticals Inc....
BioCentury | Nov 2, 1998
Company News

CpG Immuno other research news

...Human testing is expected to start late this year with a vaccine for hepatitis B. CpG ImmunoPharmaceuticals Inc....
BioCentury | Oct 19, 1998
Company News

CpG Immuno other research news

...which they suggested could be important for development of DNA vaccines or gene therapy vectors. CpG ImmunoPharmaceuticals Inc....
BioCentury | Aug 24, 1998
Company News

CpG Immuno management update

CpG ImmunoPharmaceuticals Inc., Wellesley, Mass. Business: Infectious diseases, Cancer, Autoimmune/Inflammation Hired: Robert Bratzler, as president and CEO, formerly chairman and co-founder of Encore Pharmaceuticals Inc. WIR Staff...
Items per page:
1 - 10 of 13